Thomas James Lynch
Massachusetts General Hospital
3 papers in the Anchorcite directory, published between 2004 and 2010, cited 23,730 times in total.
ORCID profileResearch topics
- Lung Cancer Treatments and Mutations · 2 papers
- Lung Cancer Research Studies · 2 papers
- Lung Cancer Diagnosis and Treatment · 2 papers
- HER2/EGFR in Cancer Research · 1 paper
- Palliative Care and End-of-Life Issues · 1 paper
- Palliative and Oncologic Care · 1 paper
Frequent co-authors
- Daniel A. Haber · 2 papers
- Daphne W. Bell · 1 paper
- Raffaella Sordella · 1 paper
- Sarada Gurubhagavatula · 1 paper
- Ross A. Okimoto · 1 paper
- Brian W. Brannigan · 1 paper
- Patricia L. Harris · 1 paper
- Sara M. Haserlat · 1 paper
Papers
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine · 2004 · 11,565 citations
BACKGROUND: Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular…
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2010 · 7,685 citations
BACKGROUND: Patients with metastatic non-small-cell lung cancer have a substantial symptom burden and may receive aggressive care at the end of life. We examined the effect of introducing palliative care early after diagnosis on patient-reported outcomes and end-of-life care among…
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine · 2010 · 4,480 citations
BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in…
Metadata from OpenAlex (CC0).